RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. IN BREVE RECORDATI S.P.A. financials
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. IN BREVE RECORDATI S.P.A.
Country: IT Reporting currency: EUR Latest annual report: 2022-12-31
LEI:
815600FBF92FD3531704 Financial statements
(EUR, as reported — unscaled; 103 line items across 2 annual periods)
| Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | €1.85B | €1.58B |
| Cost of sales | €566.7M | €427.7M |
| Gross profit | €1.29B | €1.15B |
| Operating profit (EBIT) | €437.3M | €490.2M |
| Profit before tax | €401.4M | €463.3M |
| Income tax expense | €89.1M | €77.4M |
| Profit for the year | €312.3M | €386.0M |
| — attributable to owners | €312.3M | €386.0M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | €322.9M | €380.4M |
| Cash flow statement | ||
| Net cash from operating activities | €461.7M | €491.6M |
| Net cash from investing activities | -€767.1M | -€87.5M |
| Purchase of PP&E (capex) | €23.9M | €21.9M |
| Purchase of intangibles | €72.5M | €65.5M |
| Net cash from financing activities | €341.3M | -€355.9M |
| Dividends paid | €230.6M | €216.7M |
| Lease liability payments | €10.2M | €9.2M |
| Balance sheet | ||
| Total assets | €4.00B | €2.82B |
| Non-current assets | €2.81B | €1.97B |
| Intangible assets & goodwill | €780.1M | €553.2M |
| Current assets | €1.17B | €850.1M |
| Trade & other receivables | €361.9M | €307.8M |
| Cash & equivalents | €284.7M | €244.6M |
| Total equity | €1.55B | €1.38B |
| — attributable to owners | €1.55B | €1.38B |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €1.53B | €808.2M |
| Current liabilities | €923.7M | €626.4M |
| Deferred tax liabilities | €167.9M | €26.7M |
| Derived metrics | ||
| Free cash flow | €437.8M | €469.8M |
| Operating margin | 23.6% | 31.0% |
| Net margin | 16.9% | 24.4% |
| Return on equity | 20.2% | 27.9% |
| Cash conversion ratio | 1.48× | 1.27× |
| Capex coverage | 19.33× | 22.50× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €98.5M | €72.3M |
| Adjustments For Decrease Increase In Inventories | €65.8M | -€17.5M |
| Adjustments For Decrease Increase In Trade Account Receivable | €21.2M | €43.8M |
| Adjustments For Depreciation Expense | €27.3M | €25.3M |
| Adjustments For Finance Income Cost | €30.7M | €17.8M |
| Adjustments For Income Tax Expense | €89.1M | €77.4M |
| Adjustments For Increase Decrease In Trade Account Payable | -€25.6M | -€46.3M |
| Adjustments For Sharebased Payments | €8.3M | €5.1M |
| Basic Earnings Loss Per Share From Continuing Operations | €0.00 | €0.00 |
| Cash Flows From Used In Increase Decrease In Current Borrowings | €67.3M | -€1.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €631.0M | €581.2M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €673.3M | €304.0K |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | €322.9M | €380.4M |
| Current Provisions | €16.2M | €21.4M |
| Current Tax Liabilities Current | €33.6M | €29.5M |
| Deferred Tax Assets | €76.9M | €75.9M |
| Derivative Financial Assets Held For Hedging | €23.6M | €11.1M |
| Derivative Financial Liabilities Held For Hedging | €17.4M | €14.2M |
| Diluted Earnings Loss Per Share From Continuing Operations | €0.00 | €0.00 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €4.3M | €7.7M |
| Equity and Liabilities | €4.00B | €2.82B |
| General and Administrative Expense | €109.5M | €84.5M |
| Income Taxes Paid Refund Classified As Operating Activities | -€89.8M | -€91.6M |
| Increase Decrease In Cash and Cash Equivalents | €35.8M | €48.2M |
| Increase Decrease In Working Capital | -€61.4M | €20.1M |
| Increase Decrease Through Sharebased Payment Transactions | €8.3M | €5.1M |
| Increase Decrease Through Transfers and Other Changes Equity | €102.3M | €1.5M |
| Intangible Assets Other Than Goodwill | €1.76B | €1.14B |
| Interest Paid Classified As Operating Activities | -€20.1M | -€18.3M |
| Interest Received Classified As Operating Activities | €1.9M | €291.0K |
| Inventories Total | €424.1M | €228.7M |
| Issued Capital | €26.1M | €26.1M |
| Noncurrent Assets Or Disposal Groups Classified As Held For Distribution To Owners | €12.5M | €0 |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | €28.9M | €34.1M |
| Noncurrent Provisions For Employee Benefits | €19.4M | €21.0M |
| Other Adjustments For Noncash Items | €70.8M | €12.9M |
| Other Comprehensive Income | €10.6M | -€5.5M |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €6.2M | €1.7M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €8.1M | €4.2M |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | -€5.0M | -€10.8M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €1.3M | -€627.0K |
| Other Current Assets | €15.4M | €13.0M |
| Other Current Financial Liabilities | €83.4M | €8.7M |
| Other Current Liabilities | €5.7M | €6.5M |
| Other Current Payables | €251.1M | €145.2M |
| Other Current Receivables | €63.9M | €44.9M |
| Other Finance Income Cost | -€35.9M | -€26.8M |
| Other Noncurrent Assets | €9.6M | €32.9M |
| Other Operating Income Expense | -€57.0M | -€15.1M |
| Other Reserves | €62.3M | €60.2M |
| Payments To Acquire Or Redeem Entitys Shares | €52.3M | €101.8M |
| Proceeds From Noncurrent Borrowings | €1.36B | €219.1M |
| Proceeds From Sale Or Issue of Treasury Shares | €13.6M | €42.5M |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | €1.3M | €4.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €1.2M | €161.0K |
| Purchase of Treasury Shares | €52.3M | €101.8M |
| Repayments of Noncurrent Borrowings | €803.5M | €288.5M |
| Research and Development Expense | €220.1M | €166.1M |
| Reserve of Cash Flow Hedges | €5.2M | -€974.0K |
| Reserve of Exchange Differences On Translation | -€205.0M | -€213.1M |
| Retained Earnings Excluding Profit Loss For Reporting Period | €1.52B | €1.28B |
| Retained Earnings Profit Loss For Reporting Period | €312.3M | €386.0M |
| Sale Or Issue of Treasury Shares | €13.6M | €42.5M |
| Selling Expense | €462.7M | €396.4M |
| Share Premium | €83.7M | €83.7M |
| Trade and Other Current Payables To Trade Suppliers | €224.7M | €177.9M |
| Treasury Shares | €149.6M | €127.0M |
Methodology
Every line item above is a fact tagged in RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. IN BREVE RECORDATI S.P.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.